Trevena, Inc., a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TRVN
Previous Symbol
CUSIPN/A
Phone610-354-8840
Debt
Debt-to-Equity Ratio0.16
Current Ratio4.30
Quick Ratio4.30
Price-To-Earnings
Trailing P/E Ratio-0.46
Forward P/E Ratio-1.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.75 million
Price / Sales12.07
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.56 per share
Price / Book0.98
Profitability
EPS (Most Recent Fiscal Year)($1.21)
Net Income$-71,860,000.00
Net MarginsN/A
Return on Equity-94.85%
Return on Assets-51.80%
Miscellaneous
Employees51
Outstanding Shares82,320,000
Market Cap$47.81 million
OptionableOptionable
Trevena (NASDAQ:TRVN) Frequently Asked Questions
What is Trevena's stock symbol?
Trevena trades on the NASDAQ under the ticker symbol "TRVN."
How were Trevena's earnings last quarter?
Trevena Inc (NASDAQ:TRVN) released its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.07. The biopharmaceutical company had revenue of $3 million for the quarter, compared to the consensus estimate of $3 million. View Trevena's Earnings History.
When is Trevena's next earnings date?
What price target have analysts set for TRVN?
6 Wall Street analysts have issued 12 month price targets for Trevena's shares. Their forecasts range from $0.75 to $15.00. On average, they anticipate Trevena's stock price to reach $6.35 in the next year. This suggests a possible upside of 1,054.5% from the stock's current price. View Analyst Price Targets for Trevena.
What is the consensus analysts' recommendation for Trevena?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trevena.
Has Trevena been receiving favorable news coverage?
Press coverage about TRVN stock has trended somewhat positive this week, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Trevena earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the stock's share price in the immediate future.
Who are some of Trevena's key competitors?
Some companies that are related to Trevena include Zafgen (ZFGN), Lannett (LCI), Kamada (KMDA), Taiwan Liposome (TLC), Aquestive Therapeutics (AQST), Tocagen (TOCA), Urovant Sciences (UROV), MEI Pharma (MEIP), Aeglea Bio Therapeutics (AGLE), Proteostasis Therapeutics (PTI), Calithera Biosciences (CALA), Kala Pharmaceuticals (KALA), Acer Therapeutics (ACER), AcelRx Pharmaceuticals (ACRX) and Protagonist Therapeutics (PTGX).
Who are Trevena's key executives?
Trevena's management team includes the folowing people:
- Ms. Carrie L. Bourdow, CEO, Pres & Director (Age 55)
- Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory Board
- Dr. Jonathan Violin Ph.D., Sr. VP of Scientific Affairs & Investor Relations Officer (Age 43)
- Mr. John M. Limongelli, Chief Admin. Officer, Sr. VP, Gen. Counsel & Corp. Sec. (Age 48)
- Mr. Michael Catalano, VP of Marketing
Who are Trevena's major shareholders?
Trevena's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (6.23%), Vanguard Group Inc. (3.18%), Vanguard Group Inc (3.18%), BlackRock Inc. (2.46%), Northpointe Capital LLC (1.37%) and Renaissance Technologies LLC (1.06%). View Institutional Ownership Trends for Trevena.
Which major investors are selling Trevena stock?
Which major investors are buying Trevena stock?
TRVN stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc, Vanguard Group Inc., Renaissance Technologies LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for Trevena.
How do I buy shares of Trevena?
Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trevena's stock price today?
One share of TRVN stock can currently be purchased for approximately $0.55.
How big of a company is Trevena?
Trevena has a market capitalization of $47.81 million and generates $3.75 million in revenue each year. The biopharmaceutical company earns $-71,860,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Trevena employs 51 workers across the globe.
What is Trevena's official website?
How can I contact Trevena?
Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected]
MarketBeat Community Rating for Trevena (NASDAQ TRVN)
MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe TRVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
